Oral sildenafil in the treatment of erectile dysfunction (Reprinted with permission from N Engl J Med, vol 338, pg 1397-1404, 1998)

被引:33
作者
Goldstein, I
Lue, TF
Padma-Nathan, H
Rosen, RC
Steers, WD
Wicker, PA
机构
关键词
D O I
10.1016/S0022-5347(02)80386-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background Sildenafil is a potent inhibitor of cyclic guanosine monophosphate in the corpus cavernosum and therefore increases the penile response to sexual stimulation, We evaluated the efficacy and safety of sildenafil, administered as needed in two sequential double-blind studies of men with erectile dysfunction of organic, psychogenic, or mixed causes. Methods In a 24-week dose-response study, 532 men were treated with oral sildenafil (25, 50, or 100 mg) or placebo. In a 12-week, flexible dose-escalation study, 329 different men were treated with sildenafil or placebo, with dose escalation to 100 mg based on efficacy and tolerance. After this dose-escalation study, 225 of the 329 men entered a 32-week, open-label extension study. We assessed efficacy according to the International Index of Erectile Function, a patient log, and a global-efficacy question. Results In the dose-response study, increasing doses of sildenafil were associated with improved erectile function (P values for increases in scores for questions about achieving and maintaining erections were <0.001). For the men receiving 100 mg of sildenafil, the mean score for the question about achieving erections was 100 percent higher after treatment than at base line (4.0 vs. 2.0 of a possible score of 5). In the last four weeks of treatment in the dose-escalation study, 69 percent of all attempts at sexual intercourse were successful for the men receiving sildenafil, as compared with 22 percent for those receiving placebo (P<0.001). The mean numbers of successful attempts per month were 5.9 for the men receiving sildenafil and 1.5 for those receiving placebo (P<0.001). Headache, flushing, and dyspepsia were the most common adverse effects in the dose-escalation study, occurring in 6 percent to 18 percent of the men. Ninety-two percent of the men completed the 32-week extension study. Conclusions Oral sildenafil is an effective, well-tolerated treatment for men with erectile dysfunction.
引用
收藏
页码:1197 / 1203
页数:7
相关论文
共 15 条
[1]
PHYSIOLOGY OF PENILE ERECTION [J].
ANDERSSON, KE ;
WAGNER, G .
PHYSIOLOGICAL REVIEWS, 1995, 75 (01) :191-236
[2]
Sildenafil, a novel effective oral therapy for male erectile dysfunction [J].
Boolell, M ;
GepiAttee, S ;
Gingell, JC ;
Allen, MJ .
BRITISH JOURNAL OF UROLOGY, 1996, 78 (02) :257-261
[3]
Boolell M, 1996, Int J Impot Res, V8, P47
[4]
ROLE OF NITRIC BRIDE IN THE PHYSIOLOGY OF ERECTION [J].
BURNETT, AL .
BIOLOGY OF REPRODUCTION, 1995, 52 (03) :485-489
[5]
DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83
[6]
IMPOTENCE AND ITS MEDICAL AND PSYCHOSOCIAL CORRELATES - RESULTS OF THE MASSACHUSETTS MALE AGING STUDY [J].
FELDMAN, HA ;
GOLDSTEIN, I ;
HATZICHRISTOU, DG ;
KRANE, RJ ;
MCKINLAY, JB .
JOURNAL OF UROLOGY, 1994, 151 (01) :54-61
[7]
Oral sildenafil in the treatment of erectile dysfunction [J].
Goldstein, I ;
Lue, TF ;
Padma-Nathan, H ;
Rosen, RC ;
Steers, WD ;
Wicker, PA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (20) :1397-1404
[8]
Kinsey A. C., 1948, SEXUAL BEHAV HUMAN M, P218
[9]
Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction [J].
Linet, OI ;
Ogrinc, FG .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (14) :873-877
[10]
Clinical guidelines panel on erectile dysfunction: Summary report on the treatment of organic erectile dysfunction [J].
Montague, DK ;
Barada, JH ;
Belker, AM ;
Levine, LA ;
Nadig, PW ;
Roehrborn, CG ;
Sharlip, ID ;
Bennett, AH .
JOURNAL OF UROLOGY, 1996, 156 (06) :2007-2011